growth momentum best margin
rais usd
ultim think iqvia result help return invest narr
back compani top-lin momentum put recent margin invest
back perspect name iqvia top pick outlook
discuss lot market concern around iqvia
margin driven invest need drive compani new busi win
view high-qual problem iqvia drive growth also
think concern around oce margin rel short-sight given initi
deploy cost follow high-margin servic revenu ultim iqvia
abil leverag leadership across biopharma servic aggreg share
core tenet invest thesi
payoff appear worth invest iqvia deliv
constant currenc growth ahead forecast revenu
clear top end manag guidanc beat
estim pleas result solut
post ex-fx growth basi ex-fx
basi exclud headwind pass-through re-assur see
iqvia new busi momentum translat continu growth acceler
compani stop though contract net book-to-bil
exclud reimburs expens well estim
analyt solut growth remain strong ex-fx vs forecast
given amount focu iqvia margin believ
guidanc bracket expect help remov overhang revenu
expect rang repres ex-fx growth
cash ebitda forecast touch prior forecast
high end repres growth y/i size
impact impli underli rang bracket expect
believ busi plan remain track new busi momentum
cost synergi share repurchas drive mid-teen ep growth next
sever year reiter overweight rate rais pt
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
idc link barclay live interact chart
overweight believ iqvia made lot
progress integr asset sinc novemb
merger quintil im yield market
share gain time above-market organ
growth compani platform
yield new busi win peer level ta
innov oce rwe improv visibl
believ iqvia valu proposit could yield
market share gain time coupl long
runway cost synergi upsid case
repres upsid cash ep
risk around deploy relat major new
award could pressur margin expans csm
segment growth could weigh near-term result
downsid case repres
downsid cash ep
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas see
persist
new top pick
ultim think iqvia result help return invest narr back
compani top-lin momentum put recent margin invest back
perspect name iqvia top pick outlook
discuss lot market concern around iqvia margin driven
invest need drive compani new busi win view
high-qual problem iqvia drive growth also think concern around
oce margin rel short-sight given initi deploy cost follow
high-margin servic revenu ultim iqvia abil leverag leadership across
biopharma servic aggreg share core tenet invest thesi
payoff appear worth invest iqvia deliv
constant currenc growth ahead forecast revenu clear
top end manag guidanc beat estim
pleas result post ex-fx
growth basi vs forecast ex-fx basi
exclud headwind pass-through re-assur see iqvia new
busi momentum translat continu growth acceler compani
stop though contract net book-to-bil exclud
reimburs expens well estim analyt solut
growth remain strong ex-fx vs forecast iqvia deliv cash ep
beat vs estim lower expect interest expens drove
major beat vs model share count also
forecast iqvia repurchas anoth share quarter complet
million quarter
given amount focu iqvia margin head new
year believ guidanc bracket expect help remov
overhang revenu expect rang repres ex-fx
growth guidanc includ estim headwind
outbreak compani say evalu best abil
cash ebitda forecast touch prior forecast
high end repres growth y/i aforement
impact state fall directli cash ebitda impli underli rang
bracket prior forecast midpoint final ep forecast
rang repres growth estim
midpoint believ busi plan remain track new busi
momentum cost synergi share repurchas drive mid-teen ep growth
given improv visibl growth rais price target
price target repres cash ep forecast
iqvia introduc guidanc revenu cash ep bracket
expect revenu expect rang repres
y/i total growth assum fx headwind contribut
 impli organ growth segment level iqvia guid
growth inclus headwind reimburs expens
ta includ contribut flat growth csm
guidanc includ estim headwind outbreak
solut segment compani say evalu best
abil compani also introduc cash ebitda forecast
touch forecast high end repres
growth y/i aforement impact state fall directli
cash ebitda impli underli rang bracket
forecast midpoint final ep forecast rang
guidanc first quarter lower expect partial due
aforement impact iqvia establish revenu guidanc
cash ebitda fx expect headwind
revenu compani also forecast cash ep
adjust revenu billion grew ex-fx y/i overal
estim billion revenu also came high end
manag guidanc currenc neutral growth
estim fx headwind revenu growth favor
forecast segment perspect strength driven across three
busi notabl upsid segment underli basi
 revenu billion grew y/i ex-fx versu
forecast compani cite pass-through headwind
growth headwind neutral impli
net growth constant currenc basi roughli contribut roughli
growth impli gross organ growth net organ growth total
revenu increas includ headwind fx revenu came
forecast billion
technolog analyt solut revenu billion grew y/i constant
currenc includ headwind fx came
forecast billion constant currenc growth beat
model contribut growth impli organ growth
quarter oce compani report new oce deal compar
four top pharma client contract
seat deploy bullish iqvia recent momentum oppc
appear gain traction iqvia leverag data edg custom
core capabl oce platform life scienc custom
system also includ tool commerci activ multi-channel
market medic affair market access assum user gener
per month revenu oce would account revenu iqvia
contract sale medic solut revenu million grew constant
currenc segment continu improv follow double-digit declin throughout
overal growth also increas tailwind fx organ
growth forecast primari driver
overal revenu estim million
iqvia post solid level new busi award quarterli book-to-
bill exclud pass-through solidli forecast
quarter roll ttm book-to-bil exclud pass-through
end iqvia contract backlog includ pass-through billion
repres growth y/i q/q view quarterli ttm book
trend healthi strong valid iqvia integr data strategi
reson custom importantli heighten level book activ
begin result infect revenu growth compani iqvia
note captur two new prefer provid agreement top pharma
client lock previous
believ iqvia continu show progress strategi develop
gener cro ceo bousbib highlight strong number win
quarter believ first increment new busi award compani
part nextgen data capabl start contribut meaning
growth importantli compani nextgen data capabl help
win busi exist client iqvia gain traction new custom
addit compani encourag win achiev leverag nextgen
platform smaller biopharma custom client base iqvia histor
under-penetrated compani note nextgen award split larg
pharma emerg biopharma quarter iqvia provid updat
smart trial oper enrol patient
estassumpt busi net y/i net y/i recogn growth burn move average burn end backlog growth net net net end backlog w/ growth growth y/i growth contribut organ growth organ barclay iqvia
ebitda million came expect million
ebitda margin came expect expand
iqvia ebitda margin
cog increas y/i core sg ex-comp y/i
remind merger im health quintil complet octob
iqvia annual mix benefit im attract margin profil
gross margin up-front technolog cost fx headwind contribut margin
iqvia cog sg revenu
ep came estim
street beat revenu came estim cash
ebitda also better expect adj ep beat primarili driven
lower interest expens expect well lower share count
iqvia ep y/i growth
flow oper posit million adjust net
incom work capit tailwind capital-expenditure million repres
revenu y/i manag repurchas million worth share
quarter iqvia remain author roughli billion iqvia
end quarter net debt ttm cash ebitda
estestestestestestestestincom statement servic growth constant currenc organ servic growth growth good revenu inc revenu inc gross margin inc expens inc compens stock comp sg total sg y/i ebitda y/i ebitda y/i adj ebit y/i annual bs annual bs debt item expens pre-tax tax earn unconsolid interest net net net y/i basic dilut y/i barclay iqvia
iqvia except ep reportedincom currenc profit inc ebitda ebit bs pre-tax pre-tax tax net net researchprior yearprior quarter barclay iqvia
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
